Skip to content
<  All Posts

GLP-1s for Sleep Apnea: Can Weight-Loss Drugs Treat OSA?

Dr. Martin Hopp MD, ENT
CLINICAL CONTENT REVIEWED BY

Dr. Martin Hopp MD, ENT

GLP-1s for Sleep Apnea: Can Weight-Loss Drugs Treat OSA?

For adults with obesity, GLP-1 medications may reduce obstructive sleep apnea (OSA) severity by promoting weight loss, which can ease pressure on the airway. In December 2024, the FDA approved Zepbound (tirzepatide) as the first medication for moderate to severe OSA in adults with obesity.

This approval has raised questions for people managing OSA, including whether a weekly injection could replace continuous positive airway pressure (CPAP) therapy or reduce the need for other treatments. GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound are widely discussed, but they are not a stand-alone cure and do not help everyone with sleep apnea.

In November 2026, two clinical trials found that orforglipron (Foundayo), a once-daily GLP-1 pill, also lowered sleep apnea severity in adults with overweight or obesity. Foundayo is FDA-approved for weight management, but it is not FDA-approved to treat sleep apnea.

This guide covers what the research shows, who is most likely to benefit, and how GLP-1s fit alongside proven treatments like CPAP and oral appliance therapy.

Key Takeaways

Key Takeaways
  • GLP-1 medications can lower sleep apnea severity in adults with obesity, mainly by helping them lose weight.
  • Zepbound (tirzepatide) is the first and only GLP-1 medication FDA-approved to treat moderate to severe OSA, and only in adults with obesity.
  • A once-daily GLP-1 pill, orforglipron (Foundayo), also lowered sleep apnea severity in two 2026 clinical trials. It is FDA-approved for weight management, not for sleep apnea.
  • In the 2024 clinical trials of tirzepatide, about half or more of people still had moderate to severe sleep apnea, or mild sleep apnea with daytime sleepiness, after a full year.
  • Sleep apnea is also driven by jaw and airway anatomy, which weight loss cannot change.
  • Many people use a GLP-1 alongside CPAP or a custom oral appliance, not instead of one.

How Can GLP-1s Help Sleep Apnea?

How Can GLP-1s Help Sleep Apnea?

GLP-1 medications help sleep apnea mainly by helping you lose weight, which takes pressure off your airway so it's less likely to collapse while you sleep. In adults with obesity, that can mean fewer breathing pauses each night and less severe OSA.

OSA happens when the muscles in your throat relax during sleep, narrowing or collapsing your airway and briefly stopping your breathing. Excess weight raises that risk. Fat stored in the tongue and the tissue around the throat can crowd the airway and make it more likely to close.

How Do GLP-1 Medications Work?

How Do GLP-1 Medications Work?

GLP-1 medications copy a natural hormone, GLP-1, that your gut releases after you eat. They slow digestion, help you feel full longer, and reduce appetite, which can lead to significant weight loss. As weight comes off, there can be less fat crowding the airway, which can relieve some of that pressure. Common examples include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Tirzepatide also mimics a second gut hormone called GIP, and Zepbound is currently the only GLP-1 medication FDA-approved to treat OSA.

Zepbound, Mounjaro, and Ozempic are weekly shots. Orforglipron (Foundayo) is a pill taken once a day, at any time, with or without food. The FDA approved it in April 2026 for weight management in adults with obesity, or with overweight and weight-related health problems.

Researchers are also studying whether these drugs improve sleep apnea in ways beyond weight loss, such as by lowering inflammation, but that research is still early.

What Does the Research Show About GLP-1s and Sleep Apnea?

Tirzepatide (Zepbound) can cut sleep apnea severity roughly in half in adults with obesity, according to two clinical trials published in 2024. After a year, it reduced breathing interruptions by about 25 to 29 per hour, compared with about 5 per hour on a placebo. Even so, about half or more of people still had moderate to severe sleep apnea, or mild sleep apnea with daytime sleepiness.

The trials, called SURMOUNT-OSA, included 469 adults with obesity and moderate to severe OSA. In one trial, people didn't use a CPAP or similar breathing machine. In the other, people continued to use one. For a year, each person took either tirzepatide or a placebo, a shot with no medicine in it.

Sleep apnea severity is measured by the apnea-hypopnea index (AHI), which is the number of times your breathing stops or becomes shallow per hour of sleep. An AHI of 30 or higher is considered severe, and 15 to 29 is moderate. Here's how AHI changed after one year with tirzepatide versus a placebo in each trial:

Sleep apnea severity (AHI)No breathing machineUsing a breathing machine
Average AHI at the start51.5 (severe)49.5 (severe)
Average AHI after 1 year with tirzepatide26.2 (moderate)20.2 (moderate)
Average AHI after 1 year with placebo46.2 (severe)44.0 (severe)
Sleep apnea went away, or became mild without daytime sleepiness42% (placebo 16%)50% (placebo 14%)

People in the trials started with severe sleep apnea, at about 50 events per hour on average. Tirzepatide cut that roughly in half, which is a big improvement. But on average, people still had moderate sleep apnea after a full year.

Can a GLP-1 Pill Help Sleep Apnea?

Can a GLP-1 Pill Help Sleep Apnea?

Orforglipron (Foundayo), a once-daily GLP-1 pill, reduced breathing interruptions by about 17 to 18 per hour after a year, compared with about 5 per hour on a placebo, according to two clinical trials published in November 2026. Most people still had sleep apnea afterward.

The trials, called ATTAIN-OSA, included 712 adults with overweight or obesity and moderate to severe OSA. As in the tirzepatide trials, people in one trial didn't use a CPAP or similar breathing machine, and people in the other continued to use one. For a year, each person took either orforglipron or a placebo pill once a day.

People taking orforglipron lost about 10% to 11% of their body weight. But they started with severe sleep apnea, at about 51 to 58 events per hour on average, so on average they still had moderate to severe sleep apnea after a year. In results reported by the drugmaker, about 20% to 32% of people taking orforglipron saw their sleep apnea go away or become mild without daytime sleepiness.

Orforglipron is not FDA-approved to treat sleep apnea, though its maker, Eli Lilly, has said it plans to apply for that approval by the end of 2026. The orforglipron and tirzepatide trials included different people, so their results can't be compared directly.

How Does Tirzepatide Compare With CPAP and Other Treatments?

How Does Tirzepatide Compare With CPAP and Other Treatments?

CPAP still lowers breathing interruptions more than tirzepatide does, according to a 2025 clinical review that combined results from many studies of sleep apnea treatments. Compared with no active treatment, tirzepatide reduced breathing interruptions during sleep by about 22 per hour, while liraglutide, an older medicine in the same drug family, reduced them by about 6 per hour. CPAP had the biggest effect, reducing interruptions by about 31 per hour.

These treatments were studied in different groups, so they were not compared directly. The authors said GLP-1 medicines might be used alongside other sleep apnea treatments, but noted that the evidence comes from only a few short-term studies.

What Are the Limits of GLP-1s for Sleep Apnea?

What Are the Limits of GLP-1s for Sleep Apnea?

GLP-1s can help, but they have real limits. Here's what to know about approval, causes of sleep apnea that weight loss can't change, timing, stopping treatment, and side effects and cost.

They are approved for a specific group

Zepbound is approved for adults with obesity and moderate to severe OSA, used together with a reduced-calorie diet and more physical activity. It is not approved for mild sleep apnea, for people without obesity, or for central sleep apnea. Foundayo is FDA-approved only for weight management, not for sleep apnea.

Weight is not the only cause of sleep apnea

Jaw position, airway shape, tongue size, and facial structure all play a role, which is why people at a healthy weight can still have OSA. As we explain in our guide to whether weight loss reduces snoring, many people still snore and stop breathing at night after losing weight.

Results take time

In the 2024 trials, the main results were measured after a full year. Weight loss on a GLP-1 is gradual, and the dose is usually raised slowly. Untreated sleep apnea during that time still affects your sleep, energy, and heart health.

Stopping often means regaining weight

In a separate 2024 clinical trial of tirzepatide for weight loss, people who stopped taking it regained 14% of their body weight within a year, while those who kept taking it continued to lose weight. How sleep apnea changes after stopping a GLP-1 has not been well studied, but regained weight can bring symptoms back.

Side effects and cost

The most common side effects of GLP-1s are gastrointestinal, such as nausea, diarrhea, and constipation, and are usually mild to moderate. In the orforglipron sleep apnea trials, about 7 in 10 people taking the pill had stomach-related side effects, compared with fewer than 4 in 10 on a placebo. Coverage also varies by plan. Medicare's temporary GLP-1 Bridge program excludes people with moderate to severe sleep apnea, though a Medicare Part D plan might still cover a GLP-1 for them. Check with your own plan about coverage and any prior authorization requirements before you start.

Can You Use a GLP-1 With CPAP or an Oral Appliance?

Can You Use a GLP-1 With CPAP or an Oral Appliance?

Yes. For most people, a GLP-1 works best as one part of a sleep apnea treatment plan, not the whole plan. In one of the 2024 trials, people kept using their CPAP or similar machine while taking tirzepatide, and their AHI still dropped by about 29 events per hour. In the orforglipron trials, people who kept using a breathing machine saw their AHI drop by about 17 events per hour. The 2025 review also described GLP-1s as a possible add-on to other treatments.

A custom oral appliance, also called a mandibular advancement device (MAD), holds your lower jaw slightly forward during sleep to keep your airway open. That addresses the anatomical side of sleep apnea that a GLP-1 cannot. It also starts working from the first night, while weight loss happens over months. At Daybreak, this is our focus. Our licensed providers prescribe custom oral appliances for snoring and sleep apnea, and you can get started from home. GLP-1s and oral appliances have not been studied together in a clinical trial, so talk with your provider about what combination makes sense for you. To compare your options side by side, see CPAP vs. oral appliances vs. surgery.

If your weight changes significantly, a follow-up sleep test can show whether your treatment still fits your needs. Do not stop CPAP or oral appliance therapy without talking to your provider first.

How Daybreak Can Help Treat Sleep Apnea Alongside a GLP-1

How Daybreak Can Help Treat Sleep Apnea Alongside a GLP-1

GLP-1 medications like Zepbound can meaningfully lower sleep apnea severity in adults with obesity. But for most people, they work best as one part of a treatment plan, not the whole plan. Weight loss takes months, and it can't change the jaw and airway anatomy that also drive OSA.

A custom oral appliance can work alongside a GLP-1 from the first night. Daybreak handles every step from home: a two-night, FDA-cleared at-home sleep test, a doctor's review and diagnosis, and, if you qualify, a prescription for an FDA-cleared, custom-fit oral appliance. The Daybreak Device is covered by most insurance, though Daybreak services are not billable to government plans such as Medicare. Take the 30-second sleep assessment to see if an oral appliance is right for you.

Frequently Asked Questions

1. Can GLP-1s cure sleep apnea?

Not for most people. In the two 2024 clinical trials, 42% to 50% of people taking tirzepatide saw their sleep apnea go away or become mild without daytime sleepiness after one year. That means about half or more still had moderate to severe sleep apnea, or mild sleep apnea with daytime sleepiness.

2. Is Ozempic approved for sleep apnea?

No. Ozempic and Wegovy (semaglutide) are not FDA-approved to treat sleep apnea. Zepbound (tirzepatide) is the only GLP-1 medication approved for moderate to severe OSA in adults with obesity.

3. Is there a GLP-1 pill for sleep apnea?

Not yet. No GLP-1 pill is FDA-approved to treat sleep apnea. Orforglipron (Foundayo) is a once-daily GLP-1 pill approved for weight management. In two 2026 clinical trials, it lowered sleep apnea severity in adults with overweight or obesity, but most people still had moderate to severe sleep apnea, or mild sleep apnea with daytime sleepiness, after a year.

4. Can I stop using my CPAP if I take Zepbound?

Not on your own. Your provider may recommend a follow-up sleep test after significant weight loss to see whether your sleep apnea has improved enough to change your treatment.

5. How long does it take a GLP-1 to improve sleep apnea?

In the 2024 trials, the main results were measured after one year. Improvement depends on how much weight you lose, which usually happens gradually over months.

6. Do I need a sleep test before starting a GLP-1 for sleep apnea?

Yes. A sleep apnea diagnosis requires a sleep test, and your AHI shows how severe it is. A home sleep test is a convenient way to get that diagnosis.

Disclosure

Dr. Martin Hopp, MD, ENT, serves as Daybreak's Medical Director.


Dr. Martin Hopp MD, ENT
ABOUT

Dr. Martin Hopp MD, ENT

Dr. Hopp is an otolaryngologist and a treatment leader in the field of Obstructive Sleep Apnea (OSA) at Cedars-Sinai Medical Center in Los Angeles.


Your Cart